TRIANA Biomedicines, Inc.
trianabio.com
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$120M
1 round on record
Latest round
$120M
Series B · Dec 2025 · 10 mo ago
Backers
4
RA Capital Management, Bessemer Venture Partners
The money's age
Fresh money
10 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 18
New executive TRIANA Biomedicines Announces the Appointment of Mohan Bala as Chief Operating Officer and Attracts Leading Experts to its Scientific Advisory Board · morningstar.com
Dec 3, 2025
Raised a round Series B $120M
May 6, 2025
New executive TRIANA Biomedicines Announces the Appointment of Caroline Germa as Chief Medical Officer and Attracts Leading Drug Discovery and Development Expert t… · The Globe and Mail
Sep 12, 2023
New executive TRIANA Biomedicines Announces the Appointments of Vito Palombella as Chief Scientific Officer and Reza Mazhari as Chief Business Officer · YahooFinance
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Dec 2025 | $120M | — | marketwatch.com |
Backed byfrom the funds' portfolios and accelerator catalogs
RA Capital Management 
Bessemer Venture Partners 
Atlas Venture 
Lightspeed Venture Partners Investors in similar startupsfunds that back the companies most like this one
backs PLEASE READ THIS AG
backs Achira
Similar startupsby what they do, their industry and backers
KiloGen Therapeutics specializes in proximity pharmacology, molecular glues, targeted protein degradation (TPD), biotechnology, drug…
Discover the future of molecular glues with Coltac Therapeutics. Using a cutting-edge bacteria-based positive selection screening system…
Magnet Biomedicine is advancing monovalent molecular glue inhibitors (MGIs) and innovative protein degraders to engage disease drivers.
Logic gated immunotherapies for cancer and autoimmune disease. Synolo Therapeutics is advancing a new class of therapeutics for cancer.
Charting a course to therapeutics for difficult-to-treat cancers.
Accent is pioneering a new class of small molecule precision cancer therapies that target critical intracellular dependencies that span…
News
TRIANA Biomedicines Announces Publication of Preclinical Data Supporting Clinical Advancement of TRI-611
LEXINGTON, Mass., September 09, 2026--TRIANA Bio announces publication of TRI-611 preclinical data supporting its therapeutic potential for ALK+ NSCLC, as single agent & with ALK TKIs.
Read more
Report
TRIANA Biomedicines Announces Publication of Preclinical Data Supporting Clinical Advancement of TRI-611
Read more
Report
TRIANA Biomedicines Announces Publication of Preclinical Data Supporting Clinical Advancement of TRI-611
Read more
Report
TRIANA Biomedicines Announces the Appointment of Mohan Bala as Chief Operating Officer and Attracts Leading Experts to its Scientific Advisory Board
Read more
Report
Triana Biomedicines: $120 Million Series B Secured To Advance Molecular Glue Degrader Pipeline
Triana Biomedicines has closed an oversubscribed $120 million Series B financing round that will accelerate development of its molecular glue degrader platform and advance its lead program, TRI-611, toward clinical proof-of-concept in patients with ALK-po
Read more
Report
TRIANA Biomedicines Announces Oversubscribed $120M Series B Financing to Advance its Molecular Glue Degrader Pipeline
Read more
Report
TRIANA Biomedicines Announces the Appointment of Caroline Germa as Chief Medical Officer and Attracts Leading Drug Discovery and Development Expert to its Scientific Advisory Board
ACCESS Newswire Press Release.
Read more
Report
Triana Biomedicines Inc.
The Nature Index tracks the affiliations of scientific articles from high-quality publications. The research profile for Triana Biomedicines Inc. reflects the research output of authors from Triana Biomedicines Inc. who published articles in the 145 journ
Read more
Report
Triana Biomedicines Inc.
The Nature Index tracks the affiliations of scientific articles from high-quality publications. The research profile for Triana Biomedicines Inc. reflects the research output of authors from Triana Biomedicines Inc. who published articles in the 145 journ
Read more
Report
TRIANA Biomedicines Announces the Appointments of Vito Palombella as Chief Scientific Officer and Reza Mazhari as Chief Business Officer
TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and rational molecular glue discovery platform to address difficult to drug disease targets, today announced the appointments of Dr. Vito Palombell
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Waltham
United States
HQ
400 Totten Pond Road, Suite 120 Waltham, MA 02451 United States
Financials
Total raised
$120M
Latest round
Series B
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series B | 2025 | $120M | Details |